QURE Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2018-09-26 | 2017 | Matthew Kapusta, Chief Executive Officer and Principal Financial Officer | 468,109 | 257,624 | 2,612,217 | 0 | 31,088 | 3,929,535 |
| 2018-09-26 | 2017 | Jonathan Garen, Chief Business Officer | 348,500 | 139,659 | 613,737 | 0 | 30,043 | 1,219,407 |
| 2018-09-26 | 2017 | Paul Firuta, Chief Commercial Officer | 350,000 | 140,261 | 613,737 | 0 | 33,212 | 1,407,492 |
| 2018-09-26 | 2017 | Harald Petry, Chief Scientific Officer | 199,769 | 0 | 1,178,292 | 0 | 486,339 | 1,943,671 |
| 2018-04-30 | 2017 | Jonathan Garen, Chief Business Officer | 348,500 | 139,659 | 613,737 | 0 | 30,043 | 1,219,407 |
| 2018-04-30 | 2017 | Matthew Kapusta, Chief Executive Officer and Principal Financial Officer | 468,109 | 257,624 | 2,612,217 | 0 | 31,088 | 3,929,535 |
| 2018-04-30 | 2017 | Harald Petry, Chief Scientific Officer | 199,769 | 0 | 1,178,292 | 0 | 486,339 | 1,943,671 |
| 2018-04-30 | 2017 | Paul Firuta, Chief Commercial Officer | 350,000 | 140,261 | 613,737 | 0 | 33,212 | 1,407,492 |
| 2017-05-01 | 2016 | Charles Richard, SVP, Research and Development Neuroscience | 352,620 | 103,814 | 69,120 | 0 | 364,110 | 1,678,664 |
| 2017-05-01 | 2015 | Daniel Soland, Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 154,494 |
| 2017-05-01 | 2016 | Daniel Soland, Chief Executive Officer | 376,730 | 0 | 0 | 0 | 28,252 | 250,488 |
| 2017-05-01 | 2015 | Matthew Kapusta, Chief Executive Officer and interim Chief Financial Officer | 350,000 | 140,000 | 0 | 0 | 175,000 | 996,294 |
| 2017-05-01 | 2016 | Matthew Kapusta, Chief Executive Officer and interim Chief Financial Officer | 379,996 | 142,325 | 111,129 | 0 | 29,230 | 1,237,640 |
| 2017-05-01 | 2015 | Charles Richard, SVP, Research and Development Neuroscience | 196,813 | 53,537 | 0 | 0 | 11,000 | 655,850 |
| 2017-05-01 | 2016 | Deya Corzo, SVP, Therapeutic area head Liver/Metabolism | 353,110 | 123,589 | 129,600 | 0 | 375,110 | 1,072,328 |
| 2017-05-01 | 2015 | Deya Corzo, SVP, Therapeutic area head Liver/Metabolism | 345,964 | 119,989 | 0 | 0 | 22,000 | 687,766 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
